President Donald Trump signed an executive order aimed at removing barriers to psychedelic drugs as potential treatments for serious mental illness on Saturday, April 18, 2026.
The announcement is driving a sharp premarket rally in shares of several clinical-stage companies developing psychedelic- and neuroactive compound-based therapies.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com